Senestech (SNES) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Robert Blum with Lytham Partners. Please go ahead. Speaker1 All right. Thanks so much, and thank you all for joining us today to discuss SenesTech's first quarter twenty twenty five financial results for the period ended 03/31/2025. With us on the call today are Joel Fruint ...

SURPRISE, Ariz., May 8, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the first quarter ended March 31, 2024. Q1 2025 Highlights Municipal Deployment: SenesTech expanded Evolve deployments across major U.S. municipalities. In Chicago's Wicker Park and Bucktown districts, early adoption has been positive. New York City ...

Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, May 1, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report first quarter 2025 financial results for the period ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company has scheduled a conference call that same day, Thursday, May 8, 2025, at 5:00 p.m. Eastern time, to review the results.First Quarter 2025 Conference Call DetailsDate and Time: Thursday, M ...

Core Insights - SenesTech, Inc. is expanding the deployment of its Evolve™ Rat Birth Control in the Wicker Park Bucktown area of Chicago, aiming to manage rodent populations without harmful toxins [1][2] - The initiative is a collaboration between SenesTech and local commerce groups, highlighting a joint effort to address urban pest control challenges [5] - Recent media coverage has noted similar deployments in other urban areas, including a pilot program in New York City and initiatives in Boston and Baltimore [3] Company Overview - SenesTech focuses on humane pest management through fertility control, with products designed to integrate into existing pest management programs, enhancing effectiveness while reducing reliance on traditional poisons [6] - The company aims to create healthier environments and cleaner cities through its innovative solutions [6] Community Engagement - A dedicated informational website has been launched for residents and business owners in the Wicker Park Bucktown area to provide updates and information about the Evolve™ program [4] - Early reports on the consumption of Evolve™ Rat indicate positive feedback, and the company is preparing for further shipments as the deployment area expands [5]

Core Insights - SenesTech, Inc. is participating in a webcast fireside chat at the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025 [1][2] - The company focuses on humane fertility control solutions for managing rodent populations, aiming to create healthier environments [3] Company Overview - SenesTech's products, such as Evolve rodent birth control, enhance pest management programs while reducing reliance on traditional poisons [3] - The company's mission includes creating cleaner cities, more efficient businesses, and healthier communities through humane and sustainable products [3] Event Details - The fireside chat is scheduled for 3:00 p.m. ET on April 1, 2025, and will be accessible via the conference home page [2] - A replay of the chat will be available through the same links, and one-on-one investor meetings can be arranged upon request [2]

Senestech (SNES) Q4 2024 Earnings Call March 12, 2025 11:48 PM ET Company Participants Robert Blum - Managing PartnerJoel Fruendt - CEO, President & DirectorTom Chesterman - CFO Conference Call Participants Sameer Joshi - Senior Equity Research Analyst Operator Good day, and welcome to the SenesTech Fourth Quarter and Fiscal Year twenty twenty four Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Pleas ...

SenesTech, Inc. (NASDAQ:SNES) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Robert Blum ??? Lytham Partners Joel Fruendt ??? Chief Executive Officer Tom Chesterman ??? Chief Financial Officer Conference Call Participants Sameer Joshi ??? H.C. Wainwright Operator Good day, and welcome to the SenesTech Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there w ...

Market Focus and Product Development - The rat control market is considered sufficient for the company's near-term focus[18]. - The company is focused on gaining market acceptance and commercial viability for its products, including ContraPest and Evolve[18]. - The company believes that its technology can be applied to other mammalian species, which may open new market opportunities[21]. - The company expects expenses to continue increasing as commercialization activities advance[18]. - The success of the company's research and development efforts is critical for future performance and product commercialization[21]. Regulatory and Compliance Issues - The company acknowledges the risks associated with obtaining regulatory approval for its product candidates[21]. - The company anticipates that first and second generation anti-coagulant rodenticides will face increased scrutiny and potential restrictions[18]. - The company asserts that Evolve qualifies for exemption from registration as a minimum risk pesticide under EPA regulations[18]. - The company is subject to compliance with Nasdaq's continued listing requirements, which is vital for maintaining its market presence[21]. - The company files reports with the SEC, ensuring transparency and compliance with information requirements[23]. Financial and Operational Risks - The company faces risks that may cause actual results to differ materially from forward-looking statements, including market acceptance of products and regulatory approvals[21]. - The company acknowledges potential product liability lawsuits that could incur substantial liabilities and limit product commercialization[21]. - The company is concerned that raising additional capital may dilute existing stockholders and restrict operations[21]. - The company recognizes that its share price is volatile, which could lead to securities class action litigation[21]. Human Resources and Talent Management - The company plans to utilize stock-based awards to attract and retain talented employees[18]. - Retaining and attracting key personnel is essential for the company's growth and operational development[21]. - The company emphasizes the importance of establishing an effective sales force and marketing infrastructure to generate significant revenue[21]. Research and Field Studies - The company believes that field research demonstrates more than 90% reduction in rat populations when integrated with pest management protocols[18]. - The company aims to establish fertility control as a standard tool in pest management across all verticals[18].

Revenue Growth - Revenue increased 70% to $501,000 in Q4 2024 compared to $295,000 in Q4 2023, driven by a 206% growth in e-commerce[4] - The Evolve™ Rat product contributed approximately 52% of Q4 2024 revenue, while the Evolve™ Mouse contributed 24%[4] Profitability - Gross profit margin improved to 60.9% in Q4 2024 from 43.7% in Q4 2023[4] - Adjusted EBITDA loss for Q4 2024 was $1.1 million, compared to $1.6 million in Q4 2023, marking the smallest quarterly loss in company history[4][7] Operating Expenses - Operating expenses decreased by 16% in Q4 2024 compared to Q4 2023[4] - The company plans to reduce expenses by approximately $2 million annually through new operating optimization initiatives[6] Net Loss - Net loss for Q4 2024 was $1.3 million, an improvement from a net loss of $1.7 million in Q4 2023[4] Cash Flow Breakeven - The revenue threshold for cash flow breakeven is expected to decrease to approximately $7 million annually, down from $12 million[6] Distribution and Packaging - The company has signed agreements for distribution of Evolve in 10 countries, with product shipments already occurring in Hong Kong, UAE, Netherlands, and Maldives[9] - The company launched new packaging options that use 87% less plastic than traditional pails, enhancing gross margins[9]

Core Viewpoint - SenesTech, Inc. has reported significant financial improvements in Q4 2024, including a 70% increase in revenue and a strategic focus on operating optimization initiatives aimed at reducing expenses by approximately $2 million annually to accelerate profitability [1][7][6]. Financial Performance - Revenue for Q4 2024 increased by 70% to $501,000 compared to $295,000 in Q4 2023, driven by a 206% growth in e-commerce [5]. - Gross profit margin improved to 60.9% in Q4 2024 from 43.7% in Q4 2023 [5]. - Operating expenses decreased by 16% in Q4 2024 compared to the same quarter in 2023 [5]. - Net loss for Q4 2024 was $1.3 million, an improvement from a net loss of $1.7 million in Q4 2023 [5]. - Adjusted EBITDA loss for Q4 2024 was $1.1 million, down from $1.6 million in Q4 2023 [5]. Key Growth Initiatives - The Evolve™ Rat product line became the largest revenue contributor, accounting for approximately 52% of Q4 2024 revenue [5]. - The Evolve™ Mouse product, launched in May 2024, contributed 24% of Q4 2024 revenue [5]. - The company has expanded its distribution through major online retailers, including Amazon and Walmart [5]. - Municipal programs for rodent contraception have been initiated in cities like New York, Baltimore, Chicago, and Boston [5]. - International distribution agreements have been signed in 10 countries, with product shipments already occurring in several regions [5]. Operating Optimization Initiatives - New initiatives are expected to reduce expenses by $2 million annually, lowering the revenue threshold for cash flow breakeven to approximately $7 million from a previous estimate of $12 million [6][8]. - The company aims to enhance operational efficiencies and streamline costs to accelerate its path to profitability [6][8]. Management Commentary - The CEO highlighted the transformational year for SenesTech, emphasizing strong financial results and the smallest quarterly Adjusted EBITDA loss in the company's history [7]. - The management is committed to a focused strategy that targets sustainable long-term success in the multi-billion-dollar rodent control market [8].